JP2011503199A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503199A5
JP2011503199A5 JP2010534194A JP2010534194A JP2011503199A5 JP 2011503199 A5 JP2011503199 A5 JP 2011503199A5 JP 2010534194 A JP2010534194 A JP 2010534194A JP 2010534194 A JP2010534194 A JP 2010534194A JP 2011503199 A5 JP2011503199 A5 JP 2011503199A5
Authority
JP
Japan
Prior art keywords
heterocyclic
condensed
nhr
benzene
cycloalkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010534194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503199A (ja
JP5450434B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/083478 external-priority patent/WO2009064938A1/en
Publication of JP2011503199A publication Critical patent/JP2011503199A/ja
Publication of JP2011503199A5 publication Critical patent/JP2011503199A5/ja
Application granted granted Critical
Publication of JP5450434B2 publication Critical patent/JP5450434B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010534194A 2007-11-16 2008-11-14 関節炎の治療方法 Expired - Fee Related JP5450434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
US60/988,479 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013232754A Division JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Publications (3)

Publication Number Publication Date
JP2011503199A JP2011503199A (ja) 2011-01-27
JP2011503199A5 true JP2011503199A5 (enExample) 2012-01-05
JP5450434B2 JP5450434B2 (ja) 2014-03-26

Family

ID=40291332

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534194A Expired - Fee Related JP5450434B2 (ja) 2007-11-16 2008-11-14 関節炎の治療方法
JP2013232754A Expired - Fee Related JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013232754A Expired - Fee Related JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Country Status (14)

Country Link
US (2) US20090176785A1 (enExample)
EP (1) EP2231159A1 (enExample)
JP (2) JP5450434B2 (enExample)
KR (1) KR101585848B1 (enExample)
CN (1) CN101969951B (enExample)
AU (1) AU2008322595B2 (enExample)
CA (1) CA2705294C (enExample)
DO (1) DOP2013000169A (enExample)
IL (2) IL205501A (enExample)
MX (1) MX2010005395A (enExample)
NZ (2) NZ601350A (enExample)
RU (2) RU2526201C2 (enExample)
WO (1) WO2009064938A1 (enExample)
ZA (1) ZA201003434B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2550258T3 (en) 2010-03-25 2015-12-07 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
PH12013501006A1 (en) 2010-11-23 2022-03-30 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2948287T3 (es) 2017-08-23 2023-09-07 Guangzhou Lupeng Pharmaceutical Company Ltd Derivados heterocíclicos condensados como inhibidores de Bcl-2 para el tratamiento de enfermedades neoplásicas
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
PH12022551091A1 (en) 2019-11-05 2024-06-24 Abbvie Deutschland Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
AU2021228622A1 (en) 2020-02-24 2022-10-13 Guangzhou Lupeng Pharmaceutical Company Ltd. Hot melt extruded solid dispersions containing a BCL2 inhibitor
US20240166646A1 (en) 2020-12-22 2024-05-23 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
WO1997013751A1 (en) * 1995-10-10 1997-04-17 Pfizer Inc. Indole carbamates as leukotriene antagonists
CN1425004A (zh) * 2000-03-21 2003-06-18 宝洁公司 含杂环侧链的n-取代的金属蛋白酶抑制剂
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
JP2007500703A (ja) * 2003-07-28 2007-01-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびlta4hモジュレーターとしてのそれらの使用
EP1663979B1 (en) * 2003-09-03 2013-10-09 RaQualia Pharma Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
TWI337608B (en) * 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Similar Documents

Publication Publication Date Title
JP2011503199A5 (enExample)
RU2012143212A (ru) Способ лечения артрита
RU2011134634A (ru) Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP5517935B2 (ja) 細胞壊死阻害剤としてのインドール及びインダゾール化合物
JP2014511869A5 (enExample)
JP2014501732A5 (enExample)
JP2005526723A5 (enExample)
JP2012522003A5 (enExample)
JP2016540742A5 (enExample)
JP2013510876A5 (enExample)
RU2012156940A (ru) Лекарственные средства, индуцирующие апоптоз, для лечения рака и иммунных и аутоиммунных заболеваний
RU2011134631A (ru) Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2008513515A5 (enExample)
JP2014521653A5 (enExample)
JP2018526413A5 (enExample)
JP2016530322A5 (enExample)
IL175609A (en) N-acylsulfonamide apoptosis promoters for use in treating diseases during which anti-apoptotic protein family members are expressed
JP2013532709A5 (enExample)
JP2014518869A5 (enExample)
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
RU2012107101A (ru) Производные пирроло[1,2-в] пиридазина как ингибиторы янус-киназы
JP2016540771A5 (enExample)
RU2013109291A (ru) Применение сигма-лигандов при индуцированной опиоидами гипералгезии
JP2010527985A5 (enExample)
JP2019535825A5 (enExample)